<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04186663</url>
  </required_header>
  <id_info>
    <org_study_id>2019-06-23</org_study_id>
    <nct_id>NCT04186663</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics of Advantage Arrest in Children</brief_title>
  <official_title>Pharmacokinetics of Advantage Arrest in Children</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Advantage Silver Dental Arrest, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of California, San Francisco</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Advantage Silver Dental Arrest, LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to characterize basic PK parameters (Cmax, t1/2, AUC) in healthy
      children to contribute to evidence for the safety of Advantage Arrest, consistent with
      Guidance for Industry--Exposure--Response Relationships (April 2003).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a topical agent where the active ingredients are applied to the teeth and eventually
      swallowed and may be absorbed through the GI tract or excreted. Minimal amounts are absorbed
      through the oral mucosa. Serum concentrations of silver and fluoride will be be proportional
      to the dose of silver and fluoride administered topically to the teeth as part of Advantage
      Arrest. This is an open label exposure-response study with up to 50 healthy children ages
      3-13 years of age. Subjects will be treated with Advantage Arrest and have one blood sample
      withdrawn at a randomly assigned time point. A minimum of 3 subjects per time point at
      2,4,6,24,48,96 and 168 hours. Serum samples will be analyzed for F and Ag.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 15, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Open label exposure--response study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Serum F</measure>
    <time_frame>Baseline to 168 hours</time_frame>
    <description>serum fluoride concentration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Serum Ag</measure>
    <time_frame>Baseline to 168 hours</time_frame>
    <description>serum silver concentration</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Dental Caries</condition>
  <arm_group>
    <arm_group_label>Advantage Arrest</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>38% silver diamine fluoride, topical, 1 drop, single application</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Silver Diamine Fluoride</intervention_name>
    <description>38% aqueous silver diamine fluoride [Ag(NH3)]2F, CAS RN 33040-28-7</description>
    <arm_group_label>Advantage Arrest</arm_group_label>
    <other_name>Advantage Arrest</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy.

          -  At least one carious lesion.

        Exclusion Criteria:

          -  Oral mucositis

          -  Any ulcerative lesions

          -  Hypersensitivity to silver

          -  Hypersensitivity to fluoride.

          -  SDF treatment within 3 months.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>13 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hellene Ellenikiotis, DDS</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hellene M Ellenikiotis, DDS</last_name>
    <phone>2062516831</phone>
    <email>hellene.ellenikiotis@ucsf.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Hellene Ellenikiotis, DDS</last_name>
    <phone>4083130166</phone>
    <email>hellene.ellenikiotis@ucsf.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of California San Francisco Clinical and Translational Science Institute</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94158</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hellene Ellenikiotis, DDS</last_name>
      <phone>408-313-0166</phone>
      <email>hellene.ellenikiotis@ucsf.edu</email>
    </contact>
    <contact_backup>
      <last_name>Hellene Ellenikiotis</last_name>
      <phone>4083130166</phone>
      <email>hellene.ellenikiotis@ucsf.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Hellene Ellenikiotis, DDS</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pinelopi Xenoudi, DDS</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yvonne Lin, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Peter Milgrom, DDS</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>November 28, 2019</study_first_submitted>
  <study_first_submitted_qc>December 4, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 5, 2019</study_first_posted>
  <last_update_submitted>July 10, 2020</last_update_submitted>
  <last_update_submitted_qc>July 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>child</keyword>
  <keyword>pharmacokinetics</keyword>
  <keyword>silver diamine fluoride</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dental Caries</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fluorides</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>June 23, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/63/NCT04186663/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

